Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell – associated neurotoxicity syndrome (ICANS) are well-known complications. Tocilizumab, a monoclonal antibody targeting the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Caimi, Paolo F., Pacheco Sanchez, Gabriela, Sharma, Ashish, Otegbeye, Folashade, Ahmed, Nausheen, Rojas, Patricio, Patel, Seema, Kleinsorge Block, Sarah, Schiavone, Jennifer, Zamborsky, Kayla, Boughan, Kirsten, Hillian, Antoinette, Reese-Koc, Jane, Maschan, Mikhail, Dropulic, Boro, Sekaly, Rafick-Pierre, de Lima, Marcos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546323/
https://www.ncbi.nlm.nih.gov/pubmed/34712233
http://dx.doi.org/10.3389/fimmu.2021.745320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546323/
https://www.ncbi.nlm.nih.gov/pubmed/34712233
http://dx.doi.org/10.3389/fimmu.2021.745320

Ejemplares similares